Research study to evaluate the efficacy and safety of adjunctive Pimavanserin in subjects with major depressive disorder and inadequate response to antidepressant treatment.
We are looking for individuals experiencing treatment-resistant symptoms of depression. This clinical research study is designed to help us understand the efficacy of Pimavanserin as an adjunctive therapy (in addition to another antidepressant) to your current SSRI/SNRI antidepressant. Participants will be randomly assigned either to receive the medication under investigation or a placebo to add to their current antidepressant medication for six weeks. Study participation will last for about 9 weeks (3 weeks screening; 6 weeks treatment) followed by a 30 days follow up period.
- Study Identifier: 832801
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required